PIK3CB and neoplasm: It is well-established that the PI3K pathway synergizes with various chemotherapeutic agents such as doxorubicin, etoposide, topotecan, cisplatin, vincristine and taxol, resulting in increased tumour sensitivity to chemotherapy [140].